Regenerative & Growth Peptides

IGF-1 LR3 Supplier China: Wholesale COA Guide

Research Use Only (RUO). Products and information are intended exclusively for qualified laboratory research. Not for human consumption, clinical treatment or diagnostic use.

IGF-1 LR3 appears in 100mcg and 1mg research presentations. Supplier pages may describe different production routes and analytical packages, so the buyer should define molecule-specific identity, quantitative content and lot traceability rather than applying a generic small-peptide checklist mechanically.

Define the exact IGF-1 LR3 material

Use the full controlled name, sequence or molecular reference, production route expectations, form, purity or compositional criteria, strength and RUO status. Distinguish IGF-1 LR3 from native IGF-1, IGF-DES and other catalog neighbors. Ask the supplier to state whether the offered material is produced by recombinant expression, synthesis or another controlled route and which site performs each operation. The route is not automatically a quality grade, but it determines which process and analytical questions are relevant.

Compare 100mcg and 1mg without unit errors

One milligram equals 1,000 micrograms, creating a tenfold difference from a 100mcg vial. Quote each presentation on its own row with units written explicitly, vial count, total nominal material, tolerance, parent lot and price basis. Do not rely on a bare number or abbreviated product code. Require labels and packing lists to show the unit clearly and prohibit silent substitution. Ask how filling and reconciliation controls prevent decimal, unit-conversion and mixed-strength errors.

Match analytics to molecule and production route

Request identity, purity or composition and quantity evidence appropriate to the exact material and route. HPLC and mass spectrometry may form part of the package, while protein-oriented materials can require additional method context. Review sample identifiers, expected molecular information, chromatograms or profiles, dates, specifications, results and authorization. Avoid claiming that one method proves every attribute. The supplier should explain method suitability and connect the tested sample to the offered parent and finished lots.

Verify quantitative content and formulation basis

Ask how 100mcg or 1mg content is assigned, what tolerance applies and whether the claim refers to net target material or total lyophilized mass. Request relevant quantitative results or controlled filling records and any formulation information necessary to interpret the amount. Keep identity, purity or composition, concentration and fill quantity separate. If the supplier cannot reconcile the batch record with total finished units and retained inventory, treat the content claim as an unresolved purchasing risk.

Review cold handling, continuity and documents

Obtain supplier-supported storage and transport conditions for unopened research material and define packaging, monitoring or excursion handling as appropriate to the agreed specification. Clarify released inventory, MOQ, testing and filling lead time, document-approval timing and change notification. The COA, analytical attachments, SDS, specification, labels, invoice and packing list must agree on product, strength, unit, lot and quantity. Receiving should preserve traceability and quarantine unexplained temperature, label or quantity deviations.

Map accountability before supplier approval

Document the legal seller, manufacturing site, analytical laboratory, filling or packaging site, inventory owner, release authority and dispatch entity for the exact SKU. A supplier may coordinate qualified partners, but the arrangement and responsibilities must be transparent. Ask who retains original records, investigates deviations and authorizes corrections. Require notification before a critical party changes. This map separates technical control from a generic factory claim and identifies who is accountable when a report, label, package or received quantity does not match the approved purchase order.

Build one comparable wholesale quotation matrix

Send every supplier the same fields: exact identity, strength, vial count, total material, target purity, identity method, quantitative-content basis, offered lot, testing status, packaging, documents, lead time and shipping term. Mark missing answers as exceptions rather than filling gaps with assumptions. Separate one-time testing or setup costs from recurring unit costs. This creates one auditable decision record for scientific, purchasing and quality reviewers and prevents the lowest-looking offer from winning simply because it describes less work.

Apply a batch-focused quality-control review

Define methods and acceptance criteria before purchase. HPLC commonly supports chromatographic purity and mass spectrometry can support identity, but neither should imply untested attributes. Check sample identifiers, dates, report numbers, units and lot relationships. Use the quality-control framework to connect each claim to evidence. Preserve original reports, record revisions and investigate contradictions before accepting the lot.

Create a documentation gate before dispatch

List the required COA, analytical attachments, SDS, specification, supported storage statement, label proof, invoice and packing list in the RFQ. Reconcile product, strength, lot, quantity and revision across documents using the documentation guide. The importer remains responsible for current destination rules. Research-use wording supports clarity but neither guarantees customs entry nor replaces destination-specific due diligence.

Qualify logistics and receiving controls

Confirm dispatch location, carrier, shipping term, packaging configuration and realistic production, release and transit windows. Reject promises of guaranteed clearance or misleading declarations. On receipt, record package condition, seals, product, strength, lot and quantity, then link internal inventory to the supplier batch. Quarantine unexplained discrepancies until a documented quality decision is completed.

Use actual performance for repeat-order approval

A controlled evaluation order should use the same specification planned for wholesale scale. Assess document accuracy, package condition, delivery time, communication and corrective response, and consider buyer-arranged testing appropriate to risk with documented sample custody. For every new lot, repeat the batch review. Require notification before changes to manufacturing, testing, filling, material specification, labels or packaging.

Related products and same-category guides

Frequently asked questions

What should a batch-specific peptide COA include?

It should identify the exact material and lot, list methods, specifications and results, and connect to applicable analytical evidence.

Does HPLC purity verify vial content?

No. Chromatographic purity and quantitative content are separate attributes requiring suitable evidence.

Can products in the same peptide category be substituted?

No. A different molecular identity or strength requires an explicit specification review and buyer approval.

Who confirms import requirements?

The importer or its broker must confirm current destination rules; supplier documents do not guarantee entry.

Request a wholesale research peptide quote

Send the exact product, strength, quantity, specification, destination, packaging and document requirements. Our B2B sourcing team will identify missing information before preparing a comparable quotation.

Request Wholesale Quote